Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 05 2021
Historique:
received: 15 01 2021
accepted: 12 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 21 10 2021
Statut: epublish

Résumé

Primary aldosteronism (PA) is associated with an increased risk of cardiometabolic diseases, especially in unilateral subtype. Despite its high prevalence, the case detection rate of PA is limited, partly because of no clinical models available in general practice to identify patients highly suspicious of unilateral subtype of PA, who should be referred to specialized centers. The aim of this retrospective cross-sectional study was to develop a predictive model for subtype diagnosis of PA based on machine learning methods using clinical data available in general practice. Overall, 91 patients with unilateral and 138 patients with bilateral PA were randomly assigned to the training and test cohorts. Four supervised machine learning classifiers; logistic regression, support vector machines, random forests (RF), and gradient boosting decision trees, were used to develop predictive models from 21 clinical variables. The accuracy and the area under the receiver operating characteristic curve (AUC) for predicting of subtype diagnosis of PA in the test cohort were compared among the optimized classifiers. Of the four classifiers, the accuracy and AUC were highest in RF, with 95.7% and 0.990, respectively. Serum potassium, plasma aldosterone, and serum sodium levels were highlighted as important variables in this model. For feature-selected RF with the three variables, the accuracy and AUC were 89.1% and 0.950, respectively. With an independent external PA cohort, we confirmed a similar accuracy for feature-selected RF (accuracy: 85.1%). Machine learning models developed using blood test can help predict subtype diagnosis of PA in general practice.

Identifiants

pubmed: 33947886
doi: 10.1038/s41598-021-88712-8
pii: 10.1038/s41598-021-88712-8
pmc: PMC8096956
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9140

Références

Hypertension. 2013 Aug;62(2):331-6
pubmed: 23753408
J Lab Clin Med. 1955 Jan;45(1):3-17
pubmed: 13233623
Methods Mol Biol. 2014;1107:105-28
pubmed: 24272434
J Clin Endocrinol Metab. 2012 Oct;97(10):3530-7
pubmed: 22918872
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464
pubmed: 30165444
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
J Endocr Soc. 2018 Mar 22;2(5):398-407
pubmed: 29687091
Hypertension. 2012 Aug;60(2):431-6
pubmed: 22733469
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31665338
J Hypertens. 2016 Nov;34(11):2253-7
pubmed: 27607462
Endocr J. 2011;58(9):711-21
pubmed: 21828936
Radiol Case Rep. 2019 Apr 18;14(7):814-818
pubmed: 31024637
Clin Endocrinol (Oxf). 2017 Apr;86(4):467-472
pubmed: 27862131
Hypertension. 2018 Mar;71(3):530-537
pubmed: 29358460
Semin Nephrol. 2006 Mar;26(2):173-81
pubmed: 16530609
Clin Endocrinol (Oxf). 2007 May;66(5):607-18
pubmed: 17492946
Cancer Inform. 2007 Feb 11;2:59-77
pubmed: 19458758
Endocr Pract. 2016 May;22(5):587-94
pubmed: 26789347
Clin Endocrinol (Oxf). 2020 Mar;92(3):206-213
pubmed: 31868939
J Hypertens. 2018 Nov;36(11):2269-2276
pubmed: 30020243
Clin Endocrinol (Oxf). 2016 Nov;85(5):696-702
pubmed: 27128234
Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699
pubmed: 28576687
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32561919
J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820
pubmed: 28385310
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Korean J Intern Med. 2013 Nov;28(6):739-42
pubmed: 24307854
Hypertension. 2014 Jan;63(1):151-60
pubmed: 24218436
J Hypertens. 2019 Jul;37(7):1513-1520
pubmed: 31145370
J Endocrinol Invest. 2020 Mar;43(3):347-355
pubmed: 31529391
J Endocr Soc. 2018 May 24;2(8):893-902
pubmed: 30057970
J Hum Hypertens. 2014 Dec;28(12):716-20
pubmed: 24694802
BMC Endocr Disord. 2020 Jul 31;20(1):115
pubmed: 32736558
J Hum Hypertens. 2017 Mar;31(3):195-199
pubmed: 27582025
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215

Auteurs

Hiroki Kaneko (H)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Hironobu Umakoshi (H)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan. umakoshi@med.kyushu-u.ac.jp.

Masatoshi Ogata (M)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Norio Wada (N)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan.

Norifusa Iwahashi (N)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Tazuru Fukumoto (T)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Maki Yokomoto-Umakoshi (M)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Yui Nakano (Y)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Yayoi Matsuda (Y)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Takashi Miyazawa (T)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Ryuichi Sakamoto (R)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan.

Yoshihiro Ogawa (Y)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka, 812-8582, Japan. yogawa@med.kyushu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH